Drugs / Wharton Jelly Mesenchymal Stromal Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06293950 | Mar 2022 → Jun 2026 overdue | autism | University of Jordan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wharton Jelly Mesenchymal Stromal Cell | “Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism” NCT06293950 ↗ |
| Known as | WJMSC | “Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism” NCT06293950 ↗ |
| Route | Intravenous | “Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.” NCT06293950 ↗ |